AI 检索
AI 阅读
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis

Emma Guttman-Yassky,Stephan Weidinger,Eric Simpson,Melinda Gooderham,Alan Irvine,Lynda Spelman,Jonathan Silverberg,Hany Elmaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Fan Emily Yang,Evangeline Pierce, Laia Bardolet,Diamant Thaci

BRITISH JOURNAL OF DERMATOLOGY（2024）

引用 0|浏览4
暂无评分
关键词
atopic dermatitis,efficacy,lebrikizumab,phase 3 trials,safety
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要